Company: APXIF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026189
Chunk: 221

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 221
---
 preliminary or permanent) which has become final and non-appealable and has the effect of
making consummation of the Transactions illegal or otherwise preventing or prohibiting consummation of the Transaction or the Merger;
(iv) by OmnigenicsAI if the SPAC Shareholders’ Approval shall not have been obtained by reason of the failure to obtain the required
vote at the SPAC Shareholders’ Meeting duly convened therefor or at any adjournment thereof; (v) by the Company upon a breach of
any representation, warranty, covenant or agreement set forth in the Business Combination Agreement on the part of OmnigenicsAI or Merger
Sub, subject to certain exceptions and cure periods set forth in the Business Combination Agreement, such that the conditions relating
to representations and warranties and certain covenants and agreements would not be satisfied; (vi) by OmnigenicsAI upon any breach of
any representation, warranty, covenant or agreement set forth in the Business Combination Agreement on the part of the Company, subject
to certain exceptions and cure periods set forth in the Business Combination Agreement, such that the conditions relating to representations
and warranties and certain covenants and agreements would not be satisfied; and (vii) by the Company if the SEC Required Financials shall
not have been delivered by OmnigenicsAI, on or prior to the applicable deadline specified in the Business Combination Agreement. As the
Outside Date has passed, either the Company or OmnigenicsAI may terminate the Business Combination Agreement (unless such party directly
or indirectly through its affiliates materially breaches or violates any representation, warranty, covenant, agreement or obligation
contained in the Business Combination Agreement and such material breach or violation is the principal cause of the failure to satisfy
a closing condition therein); however, no party to the Business Combination Agreement has elected (or expressed an intent) to do so.

In the event that the Business Combination Agreement
is terminated, all Transaction Expenses incurred in connection with the Proposed Business Combination shall be paid by the party incurring
such Transaction Expenses. If the Transactions are consummated, (a) OmnigenicsAI shall pay or cause to be paid (i) the SPAC Transaction
Expenses, subject to the SPAC Transaction Expenses Cap, and (ii) the Company Transaction Expenses at the Closing; and (b) Templar Sponsor
shall pay or cause to be paid, (i) all unpaid SPAC Transaction Expenses in excess of the applicable SPAC Transaction Expenses Cap, (ii)
any expenses